Soligenix, a biopharmaceutical company, announced it is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a thermostable subunit vaccine targeting the Bundibugyo virus, a strain of Ebola. The vaccine leverages Soligenix's ThermoVax platform, which stabilizes vaccines at high temperatures, aiding distribution in virus-endemic regions. This development is crucial as the Bundibugyo virus is causing an ongoing outbreak in Central Africa with high mortality and no approved vaccine. If funded, Soligenix aims to rapidly advance this vaccine to address urgent public health needs and improve global vaccination logistics.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Trupanion, a pet insurance provider, operates in the growing pet care market with subscription plans for cats and dogs. Despite a recent 2.68% dip, the stock has gained 4.13% over 30 days, indicating positive momentum and a potential buying opportuni...
Cass Information Systems reported strong first-quarter earnings of $0.66 per share, beating estimates, and achieved record annual net income of $35.1 million. The company is improving operational efficiency through automation and workforce reductions...
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
Citigroup lowered its price target for Ericsson to SEK 105 from SEK 110 and kept a Neutral rating after the company's Q2 2026 results missed revenue and earnings estimates. Ericsson's shares dropped over 13% due to rising component costs, especially ...
